Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells
1990

Transport of Multidrug Resistance Modulators in Tumor Cells

publication Evidence: moderate

Author Information

Author(s): M. Sehested, T. Skovsgaard, P. Buhl Jensen, E.J.F. Demant, E. Friche, N. Bindslev

Primary Institution: Herlev University Hospital

Hypothesis

Do verapamil and azidopine have similar energy-dependent accumulation patterns in wild type and resistant tumor cells?

Conclusion

Both verapamil and azidopine do not follow the multidrug resistance efflux pathway to any significant extent in resistant cells.

Supporting Evidence

  • Verapamil and azidopine accumulation was similar in both wild type and resistant cells.
  • Azidopine increased daunorubicin accumulation in resistant cells.
  • Both drugs did not appear to be transported by the multidrug resistance efflux mechanism.

Takeaway

The study looked at how two drugs, verapamil and azidopine, behave in cancer cells that are resistant to treatment. It found that these drugs don't get pushed out of the cells like other cancer drugs do.

Methodology

The study used cell lines to measure drug accumulation under different energy conditions and performed photolabeling and immunoprecipitation to analyze protein interactions.

Limitations

The study primarily focuses on in vitro conditions, which may not fully replicate in vivo environments.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication